Vosaroxin
- Generic Name
- Vosaroxin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N5O4S
- CAS Number
- 175414-77-4
- Unique Ingredient Identifier
- K6A90IIZ19
- Background
Vosaroxin is under investigation for the treatment of Leukemia, Myeloid, Acute.
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 9
- Registration Number
- NCT03338348
- Locations
- 🇩🇪
University Hospital Ulm, Ulm, Germany
🇩🇪Kliniken Essen-Süd, Evang. Krankenhaus Essen-Werden gGmbH, Essen, Germany
🇩🇪Klinikum Oldenburg, Klinik für Innere Medizin II, Oldenburg, Germany
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Multilineage DysplasiaMyeloid SarcomaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT02658487
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Hamid Sayar
- Target Recruit Count
- 2
- Registration Number
- NCT02485353
- Locations
- 🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Hospital, Indianapolis, Indiana, United States
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 3100
- Registration Number
- NCT02416388
- Locations
- 🇫🇷
CH Amiens Hôpital Sud, Amiens, France
🇫🇷CHU Angers, Angers, France
🇫🇷CH Victor Dupouy, Argenteuil, France
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 10
- Registration Number
- NCT01980056
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 35
- Registration Number
- NCT01913951
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT01893320
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Sunesis Pharmaceuticals
- Target Recruit Count
- 711
- Registration Number
- NCT01191801
- Locations
- 🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Department of Clinical Haematology and BMT Service, Royal Melbourne Hospital, Parkville, Victoria, Australia
🇦🇹Landeskrankenhaus Salzburg, Universitaetsklinik fur innere Medizin lll, Universitaetsklinikum der PMU, Salzburg, Austria
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
- Conditions
- LeukemiaAcute DiseaseMyelodysplastic SyndromesAcute Myeloid LeukemiaNonlymphocytic Leukemia
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Sunesis Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT00607997
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸University of MO Ellis Fischel Cancer Center, Columbia, Missouri, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Sunesis Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT00541866
- Locations
- 🇺🇸
HealthOne Presbyterian/St. Luke's Medical Center, Denver, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.